BioTime Inc (BTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioTime Inc (BTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH225D
  • |
  • Pages: 90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company's aesthetics products under development include Renevia , a potential treatment for facial lipoatrophy and facial aesthetics; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); product for retinal restoration; HyStem for stroke recovery; ReGlyde for viscosupplementation and drug delivery; and bone grafting products. BioTime's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. It also has interests in companies involved in offering therapeutic products in oncology and neurology, and biopsy tests for diagnosis of cancer. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.

BioTime Inc (BTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11

BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

BioTime Inc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15

BioTime Completes Acquisition Of Stem Cell Assets From Geron 16

Venture Financing 18

AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18

AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19

Partnerships 20

BioTime and Hepregen Form Joint Venture 20

Licensing Agreements 21

Processa Pharma Enters into Licensing Agreement with BioTime 21

BioTime Enters into Licensing Agreement with Hadassah Medical 22

BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23

Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24

BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25

Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26

BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27

ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28

BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29

BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30

Equity Offering 31

BioTime Completes Public Offering of Shares for USD28.8 Million 31

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33

BioTime to Raise up to USD25 Million in Private Placement of Shares 35

OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 36

BioTime Raises USD20 Million in Public Offering of Shares 37

OncoCyte Raises USD3.2 Million in Private Placement of Units 39

OncoCyte Raises USD7.3 Million in Private Placement of Units 40

BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 41

BioTime Raises USD5 Million in Private Placement of Shares 43

BioTime Raises USD20.4 Million in Private Placement of Shares 44

BioTime Raises USD8.6 Million in Private Placement of Shares 46

BioTime Raises USD29 Million in Private Placement of Shares 47

BioTime Completes Private Placement Of Shares For USD 6.4 Million 49

BioTime Announces Public Offering Of Shares For Up To USD 15 Million 50

BioTime Completes Public Offering Of Shares For USD 3.5 Million 51

BioTime Completes Private Placement Of Units For USD 9 Million 52

BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 53

BioTime Announces Private Placement Of Common Stock 55

Acquisition 56

BioIVT Acquires Ascendance Biotech 56

BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 57

BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 59

BioTime Inc-Key Competitors 60

BioTime Inc-Key Employees 61

BioTime Inc-Locations And Subsidiaries 62

Head Office 62

Other Locations & Subsidiaries 62

Joint Venture 63

Recent Developments 64

Strategy And Business Planning 64

Apr 06, 2017: BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging 64

Financial Announcements 65

Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 65

May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 67

Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 69

Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 71

Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 73

May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 75

Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 77

Corporate Communications 80

Sep 18, 2018: BioTime appoints Brian Culley as chief executive officer 80

Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 82

Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 83

Government and Public Interest 84

Jun 29, 2018: BioTime Awarded Grant from the National Institutes of Health 84

Jun 29, 2018: BioTime Awarded Grant From the NIH (National Institutes of Health) 85

May 02, 2018: AgeX Announces NIH Grant Award 86

Sep 18, 2017: BioTime Awarded Grant from the NIH 87

Product News 88

Jan 02, 2018: AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer 88

Other Significant Developments 89

Jun 19, 2017: Biotime Expands & Advances Ophthalmology Portfolio 89

Appendix 90

Methodology 90

About GlobalData 90

Contact Us 90

Disclaimer 90

List of Figures

BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

BioTime Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

BioTime Inc, Deals By Therapy Area, 2012 to YTD 2018 10

BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11

BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15

BioTime Completes Acquisition Of Stem Cell Assets From Geron 16

AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18

AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19

BioTime and Hepregen Form Joint Venture 20

Processa Pharma Enters into Licensing Agreement with BioTime 21

BioTime Enters into Licensing Agreement with Hadassah Medical 22

BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23

Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24

BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25

Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26

BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27

ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28

BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29

BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30

BioTime Completes Public Offering of Shares for USD28.8 Million 31

Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33

BioTime to Raise up to USD25 Million in Private Placement of Shares 35

OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 36

BioTime Raises USD20 Million in Public Offering of Shares 37

OncoCyte Raises USD3.2 Million in Private Placement of Units 39

OncoCyte Raises USD7.3 Million in Private Placement of Units 40

BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 41

BioTime Raises USD5 Million in Private Placement of Shares 43

BioTime Raises USD20.4 Million in Private Placement of Shares 44

BioTime Raises USD8.6 Million in Private Placement of Shares 46

BioTime Raises USD29 Million in Private Placement of Shares 47

BioTime Completes Private Placement Of Shares For USD 6.4 Million 49

BioTime Announces Public Offering Of Shares For Up To USD 15 Million 50

BioTime Completes Public Offering Of Shares For USD 3.5 Million 51

BioTime Completes Private Placement Of Units For USD 9 Million 52

BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 53

BioTime Announces Private Placement Of Common Stock 55

BioIVT Acquires Ascendance Biotech 56

BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 57

BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 59

BioTime Inc, Key Competitors 60

BioTime Inc, Key Employees 61

BioTime Inc, Subsidiaries 62

BioTime Inc, Joint Venture 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

BioTime Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17805
Site License
USD 500 INR 35610
Corporate User License
USD 750 INR 53415

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com